Never mind that the company, Biodelivery, undoubtedly has already spent millions to develop this new Suboxone competitor and obtain approval. Never mind that patients will cut the product in half regardless of whether anyone, even the FDA, tells them it’s OK.
We will all praise the Emperor’s beautiful new clothes.
I cannot yet report the result of any patient taking this enormous risk. I can only observe that this new product seems less brittle than Suboxone, so it seems unlikely to break when bent.
Regardless, let us hope competition will bring the prices of all the branded combination drugs down closer to that of generic buprenorphine.